Desde:
14/03/2020
OFF:
2 Hor
Ignorar
MENSAJE
Avisar mensaje
Mensajes
1.342
Seguidores
7
Le Ignoran
0
Siguiendo
28
Noticias
0
Gráficos
0
UsIgj:117008-25496216*
ISINVAL:56130572*
Avatar del usuario

revol

22/08/2025 11:15:08

3,76%

PHM

UsIgj:117389-25496216*
Mensaje de: quiquw Hora: 22/08/2025 11:00:27

Respuesta (5): Ver Todas

“This immediately was practice changing,” Misty Shields, MD, PhD, emphasized. “This is an area of vulnerability for patients who have extensive- stage disease , have had a brisk or meaningful response after induction chemoimmunotherapy, and then switched to immunotherapy and relapsed. Lurbinectedin plus atezolizumab is a helpful option to add for patients with extensive-stage disease in the maintenance setting to help prevent that high risk of relapse we see with immunotherapy alone.”

5
UsIgj:117008-25496213*
ISINVAL:56130572*
Avatar del usuario

revol

22/08/2025 11:14:44

3,76%

PHM

UsIgj:117389-25496213*
Mensaje de: quiquw Hora: 22/08/2025 11:00:27

Respuesta (5): Ver Todas

Shifting First-Line Maintenance Strategies Raise Questions in ES-SCLC

Data from the phase 3 IMforte trial (NCT05091567) presented at ASCO 2025 showed that in patients with ES-SCLC whose disease did not progress after first-line induction therapy with carboplatin, etoposide, and atezolizumab, first-line maintenance therapy with the combination of lurbinectedin (Zepzelca) and atezolizumab significantly improved both PFS and OS compared with atezolizumab monotherapy (Table 1).6 The median PFS was 5.4 months (95% CI, 4.2-5.8) with lurbinectedin plus atezolizumab (n = 242) vs 2.1 months (95% CI, 1.6-2.7) with atezolizumab alone (n = 241; stratified HR, 0.54; 95% CI, 0.43-0.67; 2-sided P < .0001). The median OS in these respective arms was 13.2 months (95% CI, 11.9-16.4) compared with 10.6 mont

5
UsIgj:117008-25449475*
ISINVAL:56130572*
Avatar del usuario

revol

08/08/2025 12:44:04

3,76%

PHM

https://pharmamar.com/wp-content/uploads/2025/08/PharmaMar-Corporate-Presentation-Slide-Deck-August-2025-web.pdf
grafico de la accion Pharma Mar

0
UsIgj:117008-25429514*
ISINVAL:56130572*
Avatar del usuario

revol

01/08/2025 21:53:47

3,76%

PHM

UsIgj:117389-25429514*
Mensaje de: quiquw Hora: 01/08/2025 20:43:41

Respuesta (10): Ver Todas

Todavía está por demostrar que tarlatamb sea mejor que Lurbi en el mundo real, no con un ensayo hecho a medida y comparándolo con topotecan mayormente...

10
UsIgj:117008-25422539*
ISINVAL:56130572*
Avatar del usuario

revol

31/07/2025 13:22:26

3,76%

PHM

De China 1,2 millones de royalties
0
UsIgj:117008-25409777*
ISINVAL:56130572*
Avatar del usuario

revol

29/07/2025 8:23:15

3,76%

PHM

Buenos días...
0
UsIgj:117008-25393901*
ISINVAL:56130572*
Avatar del usuario

revol

23/07/2025 13:37:38

3,76%

PHM

0
UsIgj:117008-25393900*
ISINVAL:56130572*
Avatar del usuario

revol

23/07/2025 13:37:24

3,76%

PHM

0
UsIgj:117008-25393622*
ISINVAL:56130572*
Avatar del usuario

revol

23/07/2025 12:51:08

3,76%

PHM

0
Mostrar mas Mensajes